Pharmaceuticals

Non-injectable Insulin Market 2026–2030: Forecasting Business Opportunities Ahead

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-injectable insulin market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Non-injectable Insulin Market show for the 2026–2030 period?

The non-injectable insulin market has experienced robust expansion in recent years. It is projected to grow from $2.14 billion in 2025 to $2.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. Historically, this expansion has been driven by the increasing prevalence of diabetes, a rising patient preference for non-injective therapies, continuous advancements in insulin formulation, various government initiatives promoting diabetes care, and a growing awareness about diabetes complications.

The non-injectable insulin market is projected to experience substantial expansion over the coming years. Its valuation is forecast to reach $3.41 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period stems from several factors, including technological progress in oral and inhalable insulin, the incorporation of digital health solutions, an increase in the elderly population, the development of healthcare infrastructure in developing economies, and tailored medicine strategies for diabetes management. Key trends anticipated during this period encompass oral insulin delivery mechanisms, pulmonary insulin inhalers, management of diabetes focused on the patient, non-invasive methods for monitoring and dosing, and advancements in formulations to enhance bioavailability.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What Drivers Are Shaping The Development Of The Non-injectable Insulin Market?

The increasing prevalence of obesity and diabetes is anticipated to drive the expansion of the non-injectable insulin market. Obesity is defined as an excessive accumulation of body fat, typically caused by an imbalance between energy intake (calories consumed) and energy expenditure, while diabetes mellitus, often referred to simply as diabetes, encompasses a group of metabolic disorders characterized by persistently high blood sugar levels. Non-injectable insulin is utilized in the treatment of both diabetes and obesity, with the capacity to enhance management by addressing barriers to traditional insulin therapy, offering potential weight management advantages, and providing more convenient treatment options. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This number is projected to more than double, reaching 1.3 billion people by 2050. Consequently, the escalating issues of obesity and diabetes are propelling the growth of the non-injectable insulin market.

Which Segments Are Contributing To The Growth Of The Non-injectable Insulin Market?

The non-injectable insulin market covered in this report is segmented –

1) By Insulin Type: Oral Insulin, Inhaled Insulin, Nasal Insulin, Buccal Or Sublingual Insulin, Transdermal Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Oral Insulin: Oral Insulin Tablets, Oral Insulin Capsules, Enteric-Coated Oral Insulin, Nanoparticle-Based Oral Insulin

2) By Inhaled Insulin: Dry Powder Inhaled Insulin, Aerosolized Insulin, Pulmonary Insulin Delivery Systems

3) By Nasal Insulin: Nasal Spray Insulin, Nasal Gel Insulin, Nasal Powder Insulin

4) By Buccal Or Sublingual Insulin: Buccal Spray Insulin, Sublingual Insulin Films, Oral Mucosal Insulin Drops

5) By Transdermal Insulin: Insulin Patches, Microneedle-Free Transdermal Systems, Iontophoresis-Based Insulin Delivery

Which Market Trends Are Opening Growth Opportunities In The Non-injectable Insulin Market?

Leading companies in the non-injectable insulin market are concentrating on advanced drug delivery innovations, such as needle-free oral insulin sprays, to enhance the lives of individuals who manage their diabetes through multiple insulin injections. A needle-free insulin spray provides a painless and non-invasive method for regulating blood glucose, offering a convenient choice as doses can be delivered directly into the mouth. For example, in November 2023, NiedlFree Technologies, an India-based technology platform, unveiled Ozulin, an oral insulin spray. This oral insulin spray aims to offer a more user-friendly option for people with diabetes, especially those who find traditional injectable insulin methods difficult. If approved, Ozulin could significantly impact diabetes care by presenting a more convenient and pain-free alternative to current insulin injections.

Who Are The Prominent Global Companies Shaping The Non-injectable Insulin Market Landscape?

Major companies operating in the non-injectable insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceutical, Abbott Laboratories, MannKind Corporation, Biocon Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Wockhardt Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Non-injectable Insulin Market?

North America was the largest region in the non-injectable insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-injectable Insulin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

Browse Through More Reports Similar to the Global Non-injectable Insulin Market 2026, By The Business Research Company

Non Injectable Insulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Oem Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oem-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795